First Dissemination Event of the ProCAncer-I Project in Vienna
A pleasure to be part of the European Congress of Radiology in Vienna! The ProCAncer-I project organised a Special Session presenting the vision of the project and discussing various implementation aspects
ProCAncer-I in the 44th International Engineering in Medicine and Biology Conference in Glasgow
We are looking forward to participating in the 44th IEEE International Engineering in Medicine and Biology Conference in Glasgow! The Initiative will organize a miniSymposium under the session on Biomedical Imaging and Image Processing, with the title: Trustworthy AI...
ProCAncer-I in the IEEE-MeMeA Conference in Taormina
We are looking forward to participating it the upcoming IEEE-MeMeA Conference in Taormina! The 17th edition of IEEE International Symposium on Medical Measurements and Applications will take place in Giardini Naxos, Taormina in the metropolitan area of Messina,...
2nd ProCAncer-I Project Dissemination Event in Lisbon
We are really happy to be part of the "AI and Machine Learning in Cancer Imaging 3.0 – Enhancing Healthcare through AI” event on 30th June & 1st July 2023 in Lisbon, Portugal. The event is organised jointly by the Champalimaud Foundation and the International...
1st ProCAncer-I Project Dissemination Event in Vienna
We are really happy to announce that we will be present at the ECR Congress in Vienna on 13 - 17 of July 2022. During the congress, a special Session will take place on the 15th of July, presenting and discussing on the ProCAncer-I project with the title: Building...
Data sharing for a good cause – How the Data Governance Act (DGA) will help ProCAncer- I
The European Union is actively working on improving the digital environment for the benefit of all Europeans. Professor Tsiknakis took part in a recent feature in the EU Council site on how the EU protects users online, ensures cybersecurity and facilitates the...
Use Cases mapped along the prostate cancer management continuum
Nowadays, prostate cancer is highly curable if detected in its early stages. Indeed, when organ-confined at diagnosis, the five-year survival rate of prostate cancer is close to 100%. Unfortunately, current prostate cancer diagnostic pipeline has several limitations. Prostate specific antigen (PSA) has a low sensitivity and specificity.
Introducing FUTURE-AI: Best practices for trustworthy AI in medical imaging
ProCAncer -I Project is part of the five H2020 projects that share the same vision, principles and challenges. These projects are funded under the same Action Line: AI for Health Imaging (Call: H2020-SC1-FA-DTS-2019-1): CHAIMELEON (chaimeleon.eu), EuCanImage...
D6.1 Vendor Specific AI Models
Deliverable 6.1, led by partner RADBOUDUMC, titled ”Development of Vendor-Specific AI Models,” describes the work performed in Tasks 6.1, 6.2, and 6.3 in WP6. Task 6.1 describes the ”Prospective dataupload to the platform” (Leader: RADBOUDUMC, Participants: FPO,...
D5.3 Deep Learning Master model and Radiomic Signatures
Deliverable 5.3, led by partner FCHAMPALIMAUD, contains the work performed by the ProCAncer-Iconsortium on master models using radiomics and deep learning techniques. ’Master models’ — modelswhich can act as a foundation for other models — were developed for radiomics...
D3.6 Final Data Management Plan
This deliverable based on the DoW entitled “Final Data Management Plan (DMP)” is an updatedversion of the Pro-CAncer-I project’s DMP (D3.5), in accordance with the regulations of the Pilotaction on Open Access to Research Data of the Horizon 2020 program (H2020). It...
D3.3 2nd Dissemination and Communication Activities
The deliverable (D3.3) describes all Communication and Dissemination activities that have takenplace during the period 1/4/2022-30/9/2023. Scope of the activities is to maximize the impactand the awareness of the project. All tasks have involved the whole consortium...
